October 2016: A Biotech Recap

October was a busy month for biotechnology! Here are some of the highlights:

“Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment,” The Wall Street Journal

“Merck & Co.’s immunotherapy cancer drug Keytruda received U.S. Food and Drug Administration approval as a first-line treatment for certain lung cancer patients.”

“EMA Transparency: New Clinical Reports Go Live,” Regulatory Focus

“The European Medicines Agency (EMA) on Thursday kicked off its effort to proactively publish clinical trials data with the release of clinical reports for two drugs, Kyprolis and Zurampic, via a new online database.”

“Glaxo Seeks FDA Approval for Experimental Shingles Vaccine,” Bloomberg

“GlaxoSmithKline Plc said it sought regulatory approval in the U.S. for its experimental shingles vaccine which, if successful, could generate more than $700 million in annual sales for the British drugmaker and compete with Merck & Co.’s Zostavax”

“Unicef Cuts Cost of Vaccine That Protects Against 5 Diseases,” The New York Times

“The United Nations Children’s Fund has made a deal with six vaccine manufacturers that will cut in half the price of a shot that protects children against five diseases, the fund announced last week.”

“GSK links with Fimbrion to develop UTI drug,” PharmaTimes

“GlaxoSmithKline has formed a partnership with US biotech Fimbrion Therapeutics to develop a first-in-class small molecule drug for the treatment and prevention of urinary tract infections (UTIs).”

“Heat, UMiami seek to create fetal Zika vaccine,” BioCentury

“Heat Biologics Inc. (NASDAQ:HTBX) and the University of Miami said they are collaborating to develop vaccines targeting the Zika virus and other infectious diseases based on Heat’s heat shock 90 kDa protein beta 1 (Hsp90B1; GP96; GRP94) vaccine platform. Heat CEO Jeff Wolf told BioCentury that using GP96 to induce an immune response in the placenta could allow the partners to develop the first vaccine to provide fetal protection against Zika.”

“Selexis to Provide ImmuNext with Cell Lines for Research into Treatment for MS, Autoimmune Diseases,” Multiple Sclerosis News Today

“Selexis has entered into a commercial arrangement with ImmuNext, providing that company with access to research cell banks from its SURE technology Platform (a best-in-class cell line development technology). ImmuNext will use the cell banks in further developing its anti-CD40 ligand antibody, a potential therapeutic agent for chronic autoimmune disorders such as multiple sclerosis (MS).”

References are hyperlinked for the interested.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s